Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
Identifieur interne : 003D11 ( Main/Exploration ); précédent : 003D10; suivant : 003D12Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
Auteurs : Kap-Sun Yeung [États-Unis] ; Gregory A. Yamanaka ; Nicholas A. MeanwellSource :
- Medicinal research reviews [ 0198-6325 ] ; 2006.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux (), Antiviraux (pharmacologie), Concentration inhibitrice 50, Cristallographie aux rayons X, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (métabolisme), Modèles chimiques, Modèles génétiques, Modèles moléculaires, Peptidyl-Dipeptidase A (physiologie), Protéines de l'enveloppe virale (métabolisme), Structure tertiaire des protéines, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (pathogénicité), Virus du SRAS (physiologie).
- MESH :
- anatomopathologie : Syndrome respiratoire aigu sévère.
- métabolisme : Glycoprotéines membranaires, Protéines de l'enveloppe virale.
- pathogénicité : Virus du SRAS.
- pharmacologie : Antiviraux.
- physiologie : Peptidyl-Dipeptidase A, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Anticorps monoclonaux, Concentration inhibitrice 50, Cristallographie aux rayons X, Glycoprotéine de spicule des coronavirus, Modèles chimiques, Modèles génétiques, Modèles moléculaires, Structure tertiaire des protéines, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (chemistry), Antiviral Agents (pharmacology), Crystallography, X-Ray, Inhibitory Concentration 50, Membrane Glycoproteins (metabolism), Models, Chemical, Models, Genetic, Models, Molecular, Peptidyl-Dipeptidase A (physiology), Protein Structure, Tertiary, SARS Virus (pathogenicity), SARS Virus (physiology), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (therapy), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (metabolism).
- MESH :
- chemical , chemistry : Antibodies, Monoclonal.
- chemical , metabolism : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , pharmacology : Antiviral Agents.
- chemical , physiology : Peptidyl-Dipeptidase A.
- pathogenicity : SARS Virus.
- pathology : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- therapy : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Crystallography, X-Ray, Inhibitory Concentration 50, Models, Chemical, Models, Genetic, Models, Molecular, Protein Structure, Tertiary, Spike Glycoprotein, Coronavirus.
Abstract
A novel human coronavirus (CoV) has been identified as the etiological agent that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. The spike (S) protein of this virus is a type I surface glycoprotein that mediates binding of the virus to the host receptor and the subsequent fusion between the viral and host membranes. Because of its critical role in viral entry, the S protein is an important target for the development of anti-SARS CoV therapeutics and prophylactics. This article reviews the structure and function of the SARS CoV S protein in the context of its role in virus entry. Topics that are discussed include: the interaction between the S1 domain of the SARS spike protein and the cellular receptor, angiotensin converting enzyme 2 (ACE2), and the structural features of the ectodomain of ACE2; the antigenic determinants presented by the S protein and the nature of neutralizing monoclonal antibodies that are elicited in vivo; the structure of the 4,3-hydrophobic heptad repeats HR1 and HR2 of the S2 domain and their interaction to form a six-helical bundle during the final stages of fusion. Opportunities for the design and development of anti-SARS agents based on the inhibition of receptor binding, the therapeutic uses of S-directed monoclonal antibodies and inhibitors of HR1-HR2 complex formation are presented.
DOI: 10.1002/med.20055
PubMed: 16521129
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002317
- to stream PubMed, to step Curation: 002317
- to stream PubMed, to step Checkpoint: 002002
- to stream Ncbi, to step Merge: 001412
- to stream Ncbi, to step Curation: 001412
- to stream Ncbi, to step Checkpoint: 001412
- to stream Main, to step Merge: 003E80
- to stream Main, to step Curation: 003D11
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.</title><author><name sortKey="Yeung, Kap Sun" sort="Yeung, Kap Sun" uniqKey="Yeung K" first="Kap-Sun" last="Yeung">Kap-Sun Yeung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, Connecticut 06492, USA. KapSun.Yeung@bms.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, Connecticut 06492</wicri:regionArea><wicri:noRegion>Connecticut 06492</wicri:noRegion></affiliation></author><author><name sortKey="Yamanaka, Gregory A" sort="Yamanaka, Gregory A" uniqKey="Yamanaka G" first="Gregory A" last="Yamanaka">Gregory A. Yamanaka</name></author><author><name sortKey="Meanwell, Nicholas A" sort="Meanwell, Nicholas A" uniqKey="Meanwell N" first="Nicholas A" last="Meanwell">Nicholas A. Meanwell</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16521129</idno><idno type="pmid">16521129</idno><idno type="doi">10.1002/med.20055</idno><idno type="wicri:Area/PubMed/Corpus">002317</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002317</idno><idno type="wicri:Area/PubMed/Curation">002317</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002317</idno><idno type="wicri:Area/PubMed/Checkpoint">002002</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002002</idno><idno type="wicri:Area/Ncbi/Merge">001412</idno><idno type="wicri:Area/Ncbi/Curation">001412</idno><idno type="wicri:Area/Ncbi/Checkpoint">001412</idno><idno type="wicri:doubleKey">0198-6325:2006:Yeung K:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">003E80</idno><idno type="wicri:Area/Main/Curation">003D11</idno><idno type="wicri:Area/Main/Exploration">003D11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.</title><author><name sortKey="Yeung, Kap Sun" sort="Yeung, Kap Sun" uniqKey="Yeung K" first="Kap-Sun" last="Yeung">Kap-Sun Yeung</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, Connecticut 06492, USA. KapSun.Yeung@bms.com</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, P.O. Box 5100, Wallingford, Connecticut 06492</wicri:regionArea><wicri:noRegion>Connecticut 06492</wicri:noRegion></affiliation></author><author><name sortKey="Yamanaka, Gregory A" sort="Yamanaka, Gregory A" uniqKey="Yamanaka G" first="Gregory A" last="Yamanaka">Gregory A. Yamanaka</name></author><author><name sortKey="Meanwell, Nicholas A" sort="Meanwell, Nicholas A" uniqKey="Meanwell N" first="Nicholas A" last="Meanwell">Nicholas A. Meanwell</name></author></analytic><series><title level="j">Medicinal research reviews</title><idno type="ISSN">0198-6325</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Crystallography, X-Ray</term><term>Inhibitory Concentration 50</term><term>Membrane Glycoproteins (metabolism)</term><term>Models, Chemical</term><term>Models, Genetic</term><term>Models, Molecular</term><term>Peptidyl-Dipeptidase A (physiology)</term><term>Protein Structure, Tertiary</term><term>SARS Virus (pathogenicity)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux ()</term><term>Antiviraux (pharmacologie)</term><term>Concentration inhibitrice 50</term><term>Cristallographie aux rayons X</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Modèles chimiques</term><term>Modèles génétiques</term><term>Modèles moléculaires</term><term>Peptidyl-Dipeptidase A (physiologie)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS (pathogénicité)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Peptidyl-Dipeptidase A</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Peptidyl-Dipeptidase A</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Crystallography, X-Ray</term><term>Inhibitory Concentration 50</term><term>Models, Chemical</term><term>Models, Genetic</term><term>Models, Molecular</term><term>Protein Structure, Tertiary</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Concentration inhibitrice 50</term><term>Cristallographie aux rayons X</term><term>Glycoprotéine de spicule des coronavirus</term><term>Modèles chimiques</term><term>Modèles génétiques</term><term>Modèles moléculaires</term><term>Structure tertiaire des protéines</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel human coronavirus (CoV) has been identified as the etiological agent that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. The spike (S) protein of this virus is a type I surface glycoprotein that mediates binding of the virus to the host receptor and the subsequent fusion between the viral and host membranes. Because of its critical role in viral entry, the S protein is an important target for the development of anti-SARS CoV therapeutics and prophylactics. This article reviews the structure and function of the SARS CoV S protein in the context of its role in virus entry. Topics that are discussed include: the interaction between the S1 domain of the SARS spike protein and the cellular receptor, angiotensin converting enzyme 2 (ACE2), and the structural features of the ectodomain of ACE2; the antigenic determinants presented by the S protein and the nature of neutralizing monoclonal antibodies that are elicited in vivo; the structure of the 4,3-hydrophobic heptad repeats HR1 and HR2 of the S2 domain and their interaction to form a six-helical bundle during the final stages of fusion. Opportunities for the design and development of anti-SARS agents based on the inhibition of receptor binding, the therapeutic uses of S-directed monoclonal antibodies and inhibitors of HR1-HR2 complex formation are presented.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Meanwell, Nicholas A" sort="Meanwell, Nicholas A" uniqKey="Meanwell N" first="Nicholas A" last="Meanwell">Nicholas A. Meanwell</name><name sortKey="Yamanaka, Gregory A" sort="Yamanaka, Gregory A" uniqKey="Yamanaka G" first="Gregory A" last="Yamanaka">Gregory A. Yamanaka</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Yeung, Kap Sun" sort="Yeung, Kap Sun" uniqKey="Yeung K" first="Kap-Sun" last="Yeung">Kap-Sun Yeung</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16521129
|texte= Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16521129" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |